We are live on ! Find out more
ENSC icon

Ensysce Biosciences
ENSC

12 hedge funds and large institutions have $15.9M invested in Ensysce Biosciences in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

66% more capital invested

Capital invested by funds: $9.56M → $15.9M (+$6.31M)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0% more ownership

Funds ownership: 0% → 0% (+0%)

20% less funds holding

Funds holding: 15 → 12 (-3)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
12
Holders Change
-3
Holders Change %
-20%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
4
Increased
3
Reduced
2
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$792K
2
Goldman Sachs
Goldman Sachs
New York
+$443K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$123K
4
State Street
State Street
Massachusetts
+$94.2K
5
TRCT
Tower Research Capital (TRC)
New York
+$56.5K

Top Sellers

Rank Fund Capital Flow
1
Stifel Financial
Stifel Financial
Missouri
-$283K
2
Millennium Management
Millennium Management
New York
-$115K
3
FIA
FNY Investment Advisers
New York
-$103K
4
VF
Virtu Financial
New York
-$78K
5
TSS
Two Sigma Securities
New York
-$34K
Name Holding Trade Value Shares
Change 		Change in
Stake
HVCM
1
HG Vora Capital Management
New York
$11.6M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.42M +$792K +84 New
Stifel Financial
3
Stifel Financial
Missouri
$1.02M -$283K -30 -33%
Goldman Sachs
4
Goldman Sachs
New York
$802K +$443K +47 New
Geode Capital Management
5
Geode Capital Management
Massachusetts
$474K +$123K +13 +87%
State Street
6
State Street
Massachusetts
$164K +$94.2K +10 New
TRCT
7
Tower Research Capital (TRC)
New York
$153K +$56.5K +6 +200%
Jane Street
8
Jane Street
New York
$79K +$18.8K +2 +67%
ECM
9
Evergreen Capital Management
Washington
$66K – – –
CAM
10
Cresset Asset Management
Illinois
$53K -$9.42K -1 -25%
UBS Group
11
UBS Group
Switzerland
$46K +$28.3K +3 New
WAM
12
Wolverine Asset Management
Illinois
$16K – – –
JP Morgan Chase
13
JP Morgan Chase
New York
$6K – – –
BlackRock
14
BlackRock
New York
$3K – – –
FCA
15
FinTrust Capital Advisors
South Carolina
$2K – – –
Morgan Stanley
16
Morgan Stanley
New York
$1K -$9.42K -1 Closed
FFIM
17
Founders Fund III Management
California
– -$435K -40 Closed
Millennium Management
18
Millennium Management
New York
– -$115K -11 Closed
FIA
19
FNY Investment Advisers
New York
– -$103K -9 Closed
VF
20
Virtu Financial
New York
– -$78K -7 Closed
TSS
21
Two Sigma Securities
New York
– -$34K -3 Closed
CCM
22
Covington Capital Management
California
– -$15K -1 Closed

ENSC Hedge Fund Activity: Q4 2021 in Review

12 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Ensysce Biosciences (ENSC) for Q4 2021, worth a combined $15.9M — up 66% from $9.56M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ENSC and 4 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 3 added.

The largest buyer was Vanguard Group, opening a new position worth an estimated $792K. The largest seller was Stifel Financial, cutting an estimated $283K.

  • 12 institutional investors held Ensysce Biosciences (ENSC) as of Q4 2021, down from 15 in Q3 2021.
  • Funds reported $15.9M of Ensysce Biosciences stock for Q4 2021, up 66% quarter-over-quarter.
  • 4 funds opened new Ensysce Biosciences positions in Q4 2021 and 7 closed out, a net change of -3 holders.
  • The largest Ensysce Biosciences buyer in Q4 2021 was Vanguard Group, an estimated $792K added.
  • The largest Ensysce Biosciences seller in Q4 2021 was Stifel Financial, an estimated $283K sold.

Based on aggregated 13F filings for Q4 2021.